T2 Biosystems, Inc. (TTOO)
| Market Cap | 343.26M |
| Revenue (ttm) | 13.41M |
| Net Income (ttm) | -50.93M |
| Shares Out | 147.79M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $2.48 |
| Previous Close | $2.19 |
| Change ($) | 0.29 |
| Change (%) | 13.24% |
| Day's Open | 2.28 |
| Day's Range | 2.26 - 2.64 |
| Day's Volume | 7,517,125 |
| 52-Week Range | 0.24 - 3.79 |
LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to pa...
The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.
TTOO stock is climbing on Friday after T2 Biosystems announced its Covid-19 test can detect the Brazilian strain. What should you know?
Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis
LEXINGTON, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, announced today that it issued an ind...
Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG
T2 has been a huge beneficiary of the COVID-19 pandemic, as hospitals take a second look at its revolutionary diagnostic technology. A 300% revenue gain is projected by Wall Street for 2021 vs...
Investors are excited about the prospects of the company's COVID-19 diagnostic test.
BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tisleliz...
T2 Biosystems (TTOO) stock is on the rise Tuesday following positive news concerning testing for new strains of the novel coronavirus. The post TTOO Stock: 10 Things to Know About T2 Biosystem...
As the COVID-19 virus mutates into different variants, one small-cap diagnostics company says their test can detect the mutated strains: T2 Biosystems. T2 Biosystems soared as much as 49% in T...
Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.
T2 Biosystems (TTOO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and anal...
A struggling diagnostics platform is benefiting from Sars-COVID-2 tailwinds. Its sars-COVID-2 test is accelerating the uptake of its diagnostic platform.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to pa...
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2020 Results - Earnings Call Transcript
T2 Biosystems (TTOO) delivered earnings and revenue surprises of 20.00% and 32.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of T2 Biosystems (NASDAQ:TTOO) fell 10% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 74.19% over the past year to ($0.08...
Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financia...
Is (TTOO) Outperforming Other Medical Stocks This Year?
Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Re...
Is (TTOO) Outperforming Other Medical Stocks This Year?
Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus Summit will raise awareness and highlight the critica...
Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients
The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2020 Results - Earnings Call Transcript
Shares of T2 Biosystems (NASDAQ: TTOO) decreased 7.49% in after-market trading after the company reported Q2 results.
LEXINGTON, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the ...
T2 Biosystems (NASDAQ: TTOO) announces its next round of earnings this Tuesday, August 11.
LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Director...
In the latest trading session, T2 Biosystems (TTOO) closed at $1.66, marking a +1.84% move from the previous day.
LEXINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to ...
LEXINGTON, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financ...
T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.
In the latest trading session, T2 Biosystems (TTOO) closed at $1.62, marking a +0.62% move from the previous day.
In the latest trading session, T2 Biosystems (TTOO) closed at $1.33, marking a -0.75% move from the previous day.
T2 Biosystems Inc. (NASDAQ: TTOO) solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument
Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines
LEXINGTON, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement a...
Is (TTOO) Outperforming Other Medical Stocks This Year?
LEXINGTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that on June 16, 2020 it r...
Three new appointments add significant clinical and commercialization experience and expand board diversity Three new appointments add significant clinical and commercialization experience and...
About TTOO
T2 Biosystems, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as we... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 7, 2014 |
| CEO John Sperzel | Employees 118 |
| Stock Exchange NASDAQ | Ticker Symbol TTOO |
Financial Performance
In 2019, T2 Biosystems's revenue was $8.34 million, a decrease of -20.62% compared to the previous year's $10.50 million. Losses were -$59.01 million, 15.4% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for T2 Biosystems stock is "Strong Buy." The 12-month stock price forecast is 3.18, which is an increase of 28.23% from the latest price.